MaxCyte to acquire Akron BioProducts for $151.8 million, aiming to double revenue
+2 new sources since this summary was written
MaxCyte announced a definitive agreement to purchase Akron BioProducts for a total of $151.8 million, paid with cash, stock and deferred payments. Akron Bio, a supplier of GMP‑grade reagents for cell‑therapy manufacturing, is projected to produce about $28 million of revenue and $7‑8 million of EBITDA in 2026. The deal is expected to close before the end of 2026 and should nearly double MaxCyte’s revenue base. MaxCyte has arranged financing from MidCap Financial that can provide up to $75 million, split between a term loan and a revolving line, and plans to draw $20 million from the term loan and $2 million from the revolving facility at closing.
Why it matters
The company says the acquisition will double its revenue and fund the combined business through profitability, which could improve cash‑burn and expand its product portfolio. The transaction adds debt and dilutes equity, affecting the balance sheet and future earnings.
Key facts
- 1MaxCyte agreed to acquire Akron BioProducts for $151.8 million, consisting of $105.0 million cash, roughly $26.8 million in stock (20,639,733 shares), and $20.0 million in deferred payments. investing.com
- 2Akron Bio is expected to generate approximately $28 million in revenue and $7‑8 million of EBITDA in 2026. tradingview.com
- 3The acquisition is projected to almost double MaxCyte’s revenue base. tradingview.com
- 4The transaction is slated to close before the end of 2026, subject to customary closing conditions. investing.com
- 5MaxCyte arranged a credit facility with MidCap Financial that can provide up to $75.0 million, comprising a $55.0 million term loan and a $20.0 million revolving line. investing.com
- 6At closing, MaxCyte intends to draw $20.0 million from the term loan and $2.0 million from the revolving facility. investing.com
Summary written by AlphAI AI Desk from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.